HCV combination therapy containing ribavirin in association with antioxidants

An anti-oxidant, ribavirin technology, applied in the field of pharmaceuticals to improve ribavirin-related hemolysis, can solve the problem of reducing

Inactive Publication Date: 2002-06-26
SCHERING AG
View PDF17 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, this combination therapy is not always effective due to concomitant ribavirin side effects such as ribavirin-related hemolysis (measured by decreased hemoglobin concentration)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] The present invention provides methods and pharmaceutical compositions for treating susceptible viral infections, especially hepatitis C virus infections.

[0017] The term "susceptible viral infection" as used herein means a viral infection caused by a wide range of RNA and DNA viruses, including but not limited to virus families, such as the flavirus genus including flaviviruses and Kuning virus It is a member of pestivirus (pestivirus), hepatitis virus (hepavirus) of which hepatitis C virus is a member, and arbovirus, orthomyxovirus, and paramyxovirus of which West Nile virus is a member , Arena virus, Bunyang virus, herpes virus, adenovirus, pox virus and retrovirus.

[0018] Typical suitable "susceptible viral infections" include influenza A and B virus infections, parainfluenza virus infections, respiratory syncytial virus ("RSV") infections such as RSV bronchiolitis and RSV pneumonia, especially RSV infections in infants and young children and previous RSV pneumonia,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods of treating patients having susceptible viral infections, especially chronic hepatitis C infection by administering to said patient a thereapeutically effective amount of a combination therapy of interferon-alfa and ribavirin for a time sufficient to lower HCV-RNA in association with a therapeutically effective amount of an antioxidant for a time sufficient to ameliorate ribavirin-related hemolysis are disclosed.

Description

Background of the invention [0001] The present invention relates to the preparation of a medicament for improving ribavirin-related hemolysis by using antioxidants, and the hemolysis is related to the treatment of susceptible viral infections with ribavirin. [0002] The treatment of patients who are susceptible to viral infections, especially chronic hepatitis C virus infections, includes administering to the patient a therapeutically effective amount of a-interferon and ribavirin combined therapy, the course of which is sufficient to reduce HCV-RNA, and at the same time A therapeutically effective amount of antioxidants is given, and the course of treatment is sufficient to improve ribavirin-related hemolysis. [0003] Chronic hepatitis C virus infection is a particularly insidious and slowly progressing viral disease that has a significant impact on the quality of life. It can eventually lead to liver cirrhosis, decompensated liver disease and / or hepatocellular carcinoma. [00...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/01A61K31/05A61K31/07A61K31/10A61K31/122A61K31/198A61K31/355A61K31/375A61K31/7056A61K33/04A61K38/21A61P7/06A61P31/00A61P31/12A61P39/06A61P43/00
CPCA61K38/212A61P31/00A61P31/12A61P39/06A61P43/00A61P7/06A61K31/70A61K31/355A61K2300/00
Inventor C·A·布拉斯P·W·格吕E·皮肯
Owner SCHERING AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap